Intelon Optics is pleased to announce that it has received clearance from the U.S. Food and Drug Administration (FDA) for its innovative anterior eye segment analysis device. This groundbreaking device is the first to leverage the principles of Brillouin technology to assess the biomechanics of the eye.

The Intelon BOSS device is intended for imaging the cornea and crystalline lens, as well as measuring the elastic properties of these ocular structures. "We are excited to have received FDA clearance for our BOSS device," said Dimitri, COO of Intelon Optics. "BOSS offers eyecare professionals critical insights into the elastic properties of the cornea and crystalline lens tissues, displayed as a map and/or individual axial scans"

Extensive testing has confirmed that the BOSS device is both safe and effective for measuring the longitudinal elastic modulus of the cornea and crystalline lens. The device consistently delivers repeatable and reproducible results, making it a valuable tool for eye care professionals.

This FDA clearance marks a significant milestone for Intelon Optics, enabling the BOSS system to expand its market presence with its cutting-edge technology. The company remains committed to ongoing research and development to further enhance the BOSS device's capabilities. Intelon Optics plans to commercialize the BOSS system later this year.